• Je něco špatně v tomto záznamu ?

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)

R. Aymon, D. Mongin, SA. Bergstra, D. Choquette, C. Codreanu, D. De Cock, L. Dreyer, O. Elkayam, D. Huschek, KL. Hyrich, F. Iannone, N. Inanc, L. Kearsley-Fleet, SS. Koca, TK. Kvien, BF. Leeb, G. Lukina, DC. Nordström, K. Pavelka, M....

. 2024 ; 83 (4) : 421-428. [pub] 20240312

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu pozorovací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006744

BACKGROUND: In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis factor inhibitors (TNFi) adalimumab or etanercept. OBJECTIVE: Compare treatment discontinuations for adverse events (AEs) among second-line therapies in an international real-world RA population. METHODS: Patients initiating JAKi, TNFi or a biological with another mode of action (OMA) from 17 registers participating in the 'JAK-pot' collaboration were included. The primary outcome was the rate of treatment discontinuation due to AEs. We used unadjusted and adjusted cause-specific Cox proportional hazard models to compare treatment discontinuations for AEs among treatment groups by class, but also evaluating separately the specific type of JAKi. RESULTS: Of the 46 913 treatment courses included, 12 523 were JAKi (43% baricitinib, 40% tofacitinib, 15% upadacitinib, 2% filgotinib), 23 391 TNFi and 10 999 OMA. The adjusted cause-specific hazard rate of treatment discontinuation for AEs was similar for TNFi versus JAKi (1.00, 95% CI 0.92 to 1.10) and higher for OMA versus JAKi (1.11, 95% CI 1.01 to 1.23), lower with TNFi compared with tofacitinib (0.81, 95% CI 0.71 to 0.90), but higher for TNFi versus baricitinib (1.15, 95% CI 1.01 to 1.30) and lower for TNFi versus JAKi in patients 65 or older with at least one cardiovascular risk factor (0.79, 95% CI 0.65 to 0.97). CONCLUSION: While JAKi overall were not associated with more treatment discontinuations for AEs, subgroup analyses suggest varying patterns with specific JAKi, such as tofacitinib, compared with TNFi. However, these observations should be interpreted cautiously, given the observational study design.

5 A Nasonova Research Institute of Rheumatology A S Loginov Moscow Clinical Scientific Center Moscow Russian Federation

Austrian registry for Biologics Biosimilars und targeted synthetic DMARDs in the treatment of rheumatic diseases BioReg Vienna Austria

Biostatistics and Medical Informatics Research Group Department of Public Health Vrije Universiteit Brussel Brussel Belgium

Center for Rheumatic Diseases University of Bucharest Bucuresti Romania

Center for treatment of Rheumatic and Musculoskeletal Diseases Diakonhjemmet Hospital Oslo Norway

Centre for Epidemiology Versus Arthritis The University of Manchester Manchester UK

Department of Rheumatology and University of Ljubljana Faculty of Medicine University Medical Centre Ljubljana Ljubljana Ljubljana Slovenia

DiMePRe J Rheumatology Unit University of Bari Bari Puglia Italy

Division of Medicine ROB FIN Helsinki University and Helsinki University Hospital Helsinki Finland

Division of Rheumatology Firat University Faculty of Medicine Elazig Turkey

Division of Rheumatology Geneva University Hospitals Geneve Switzerland

Institut de recherche en Rhumatologie CHUM Montreal Quebec Canada

Manchester University NHS Foundation Trust NIHR Manchester Biomedical Research Centre Manchester UK

Programme Area Epidemiology DRFZ Berlin Germany

Rheumatology DANBIO Aalborg University Hospital Aalborg North Denmark Region Denmark

Rheumatology Division Geneva University Hospitals Geneve Switzerland

Rheumatology Hospital Clinico Universitario Santiago de Compostela Spain

Rheumatology Institute of Rheumatology Praha Czech Republic

Rheumatology Leiden University Medical Center Leiden The Netherlands

Rheumatology Marmara University School of Medicine Istanbul Turkey

Rheumatology Research Unit Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Lisbon Portugal

Rheumatology Tel Aviv University Tel Aviv Israel

Skeletal Biology and Engineering research Center KU Leuven Leuven Flanders Belgium

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006744
003      
CZ-PrNML
005      
20240423155457.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/ard-2023-224670 $2 doi
035    __
$a (PubMed)38071508
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Aymon, Romain $u Rheumatology Division, Geneva University Hospitals, Geneve, Switzerland romain.aymon@hcuge.ch $1 https://orcid.org/0000000328543632
245    10
$a Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study) / $c R. Aymon, D. Mongin, SA. Bergstra, D. Choquette, C. Codreanu, D. De Cock, L. Dreyer, O. Elkayam, D. Huschek, KL. Hyrich, F. Iannone, N. Inanc, L. Kearsley-Fleet, SS. Koca, TK. Kvien, BF. Leeb, G. Lukina, DC. Nordström, K. Pavelka, M. Pombo-Suarez, A. Rodrigues, Z. Rotar, A. Strangfeld, P. Verschueren, R. Westermann, J. Zavada, DS. Courvoisier, A. Finckh, K. Lauper
520    9_
$a BACKGROUND: In a clinical trial setting, patients with rheumatoid arthritis (RA) taking the Janus kinase inhibitor (JAKi) tofacitinib demonstrated higher adverse events rates compared with those taking the tumour necrosis factor inhibitors (TNFi) adalimumab or etanercept. OBJECTIVE: Compare treatment discontinuations for adverse events (AEs) among second-line therapies in an international real-world RA population. METHODS: Patients initiating JAKi, TNFi or a biological with another mode of action (OMA) from 17 registers participating in the 'JAK-pot' collaboration were included. The primary outcome was the rate of treatment discontinuation due to AEs. We used unadjusted and adjusted cause-specific Cox proportional hazard models to compare treatment discontinuations for AEs among treatment groups by class, but also evaluating separately the specific type of JAKi. RESULTS: Of the 46 913 treatment courses included, 12 523 were JAKi (43% baricitinib, 40% tofacitinib, 15% upadacitinib, 2% filgotinib), 23 391 TNFi and 10 999 OMA. The adjusted cause-specific hazard rate of treatment discontinuation for AEs was similar for TNFi versus JAKi (1.00, 95% CI 0.92 to 1.10) and higher for OMA versus JAKi (1.11, 95% CI 1.01 to 1.23), lower with TNFi compared with tofacitinib (0.81, 95% CI 0.71 to 0.90), but higher for TNFi versus baricitinib (1.15, 95% CI 1.01 to 1.30) and lower for TNFi versus JAKi in patients 65 or older with at least one cardiovascular risk factor (0.79, 95% CI 0.65 to 0.97). CONCLUSION: While JAKi overall were not associated with more treatment discontinuations for AEs, subgroup analyses suggest varying patterns with specific JAKi, such as tofacitinib, compared with TNFi. However, these observations should be interpreted cautiously, given the observational study design.
650    _2
$a lidé $7 D006801
650    12
$a antirevmatika $x terapeutické užití $7 D018501
650    12
$a inhibitory Janus kinas $x terapeutické užití $7 D000075242
650    _2
$a výsledek terapie $7 D016896
650    _2
$a TNF-alfa $7 D014409
650    12
$a revmatoidní artritida $x farmakoterapie $7 D001172
650    _2
$a inhibitory TNF $x terapeutické užití $7 D000079424
650    12
$a azetidiny $7 D001384
650    12
$a puriny $7 D011687
650    12
$a pyrazoly $7 D011720
650    12
$a sulfonamidy $7 D013449
655    _2
$a pozorovací studie $7 D064888
655    _2
$a časopisecké články $7 D016428
700    1_
$a Mongin, Denis $u Rheumatology Division, Geneva University Hospitals, Geneve, Switzerland $1 https://orcid.org/0000000248018395
700    1_
$a Bergstra, Sytske Anne $u Rheumatology, Leiden University Medical Center, Leiden, The Netherlands $1 https://orcid.org/0000000271365248
700    1_
$a Choquette, Denis $u Institut de recherche en Rhumatologie, CHUM, Montreal, Quebec, Canada
700    1_
$a Codreanu, Catalin $u Center for Rheumatic Diseases, University of Bucharest, Bucuresti, Romania
700    1_
$a De Cock, Diederik $u Biostatistics and Medical Informatics Research Group, Department of Public Health, Vrije Universiteit Brussel, Brussel, Belgium
700    1_
$a Dreyer, Lene $u Rheumatology, DANBIO, Aalborg University Hospital, Aalborg, North Denmark Region, Denmark
700    1_
$a Elkayam, Ori $u Rheumatology, Tel Aviv University, Tel Aviv, Israel
700    1_
$a Huschek, Doreen $u Programme Area Epidemiology, DRFZ, Berlin, Germany
700    1_
$a Hyrich, Kimme L $u Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK $u Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester, UK $1 https://orcid.org/0000000182429262
700    1_
$a Iannone, Florenzo $u DiMePRe-J -Rheumatology Unit, University of Bari, Bari, Puglia, Italy $1 https://orcid.org/0000000304745344
700    1_
$a Inanc, Nevsun $u Rheumatology, Marmara University School of Medicine, Istanbul, Turkey $1 https://orcid.org/0000000328620562
700    1_
$a Kearsley-Fleet, Lianne $u Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK $1 https://orcid.org/0000000303771575
700    1_
$a Koca, Suleyman Serdar $u Division of Rheumatology, Firat University, Faculty of Medicine, Elazig, Turkey
700    1_
$a Kvien, Tore K $u Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
700    1_
$a Leeb, Burkhard F $u Austrian registry for Biologics, Biosimilars und targeted synthetic DMARDs (ts-DMARDs) in the treatment of rheumatic diseases, BioReg, Vienna, Austria
700    1_
$a Lukina, Galina $u V.A.Nasonova Research Institute of Rheumatology, A.S.Loginov Moscow Clinical Scientific Center, Moscow, Russian Federation
700    1_
$a Nordström, Dan C $u Division of Medicine, ROB-FIN, Helsinki University and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Pavelka, Karel $u Rheumatology, Institute of Rheumatology, Praha, Czech Republic
700    1_
$a Pombo-Suarez, Manuel $u Rheumatology, Hospital Clinico Universitario, Santiago de Compostela, Spain $1 https://orcid.org/0000000225244883
700    1_
$a Rodrigues, Ana $u Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Lisbon, Portugal
700    1_
$a Rotar, Ziga $u Department of Rheumatology & University of Ljubljana, Faculty of Medicine, University Medical Centre Ljubljana, Ljubljana, Ljubljana, Slovenia
700    1_
$a Strangfeld, Anja $u Programme Area Epidemiology, DRFZ, Berlin, Germany $1 https://orcid.org/000000026233022X
700    1_
$a Verschueren, Patrick $u Skeletal Biology and Engineering research Center, KU Leuven, Leuven, Flanders, Belgium $1 https://orcid.org/0000000203403580
700    1_
$a Westermann, Rasmus $u Rheumatology, DANBIO, Aalborg University Hospital, Aalborg, North Denmark Region, Denmark
700    1_
$a Zavada, Jakub $u Rheumatology, Institute of Rheumatology, Praha, Czech Republic
700    1_
$a Courvoisier, Delphine Sophie $u Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland $1 https://orcid.org/0000000219562607
700    1_
$a Finckh, Axel $u Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland $1 https://orcid.org/0000000212104347
700    1_
$a Lauper, Kim $u Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland $1 https://orcid.org/0000000243159009
773    0_
$w MED00000444 $t Annals of the rheumatic diseases $x 1468-2060 $g Roč. 83, č. 4 (2024), s. 421-428
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38071508 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155454 $b ABA008
999    __
$a ok $b bmc $g 2081000 $s 1216511
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 83 $c 4 $d 421-428 $e 20240312 $i 1468-2060 $m Annals of the rheumatic diseases $n Ann Rheum Dis $x MED00000444
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace